Giuseppe Mancuso, member responsible for animal welfare, and Prof
Semaglutide is currently being investigated in two large phase III clinical trial programs for treating obesity: the STEP program, which aims to obtain regulatory approval for semaglutide as an anti-obesity drug and is evaluating cardiovascular outcomes in 17,500 patients
Benekareddy M, Goodfellow NM, Lambe EK, Vaidya VA
Being a slow responder to GLP-1 medications (like semaglutide or tirzepatide) does not mean the medication has failed and it does not mean your body is broken
It also reduces the severity of symptoms and decreases the duration of active bacterial or viral infections
Journal of Advanced Nursing, 75 (1), 3042